Imodium Instants (Loperamide Hydrochloride)

• Loperamide acts on the gastrointestinal motility pathway to control diarrheal conditions.
• Acute nonspecific diarrhea: decreases stool frequency and urgency by slowing intestinal transit and enhancing fluid absorption.
• Chronic diarrhea: offers symptomatic control through reduced motility, helping to normalize stool form and frequency over longer periods.
• Irritable bowel syndrome with diarrhea (IBS‑D): mitigates frequent loose stools and abdominal discomfort by modulating gut motility and water balance.

• Loperamide is a peripheral μ‑opioid receptor agonist that binds to μ‑receptors in the myenteric plexus of the intestinal wall. Activation of these receptors inhibits acetylcholine release, reduces smooth‑muscle contractions, and prolongs transit time, allowing greater absorption of water and electrolytes. Because it does not readily cross the blood‑brain barrier, central opioid effects are minimal and it provides antidiarrheal action without typical opioid‑related sedation or dependence.

Loperamide may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Abdominal cramps: mild to moderate discomfort in the abdomen.
• Constipation: reduced bowel movements or hard stools.
• Nausea: feeling of queasiness.
• Flatulence: increased intestinal gas.

Serious or Rare Side Effects

• Severe constipation or intestinal obstruction: risk of blockage requiring medical attention.
• Toxic megacolon: rare but life‑threatening dilation of the colon.
• Allergic reactions: rash, itching, swelling, or anaphylaxis.

When using Loperamide, certain precautions should be observed to ensure safe and effective therapy.

• Assess underlying cause: confirm that diarrhea is not due to infection before use.
• Avoid in bacterial enterocolitis: risk of worsening infection.
• Limit duration: discontinue if symptoms persist beyond 48 hours without improvement.
• Use with caution in hepatic impairment: drug metabolism may be reduced.
• Avoid concomitant use with strong CYP3A4 inhibitors: may increase systemic exposure.
• Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture.

Loperamide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise plasma levels and increase risk of serious cardiac effects.
• P-glycoprotein inhibitors (e.g., quinidine, verapamil): can enhance central exposure and precipitate toxicity.

Moderate Interactions (Monitor Closely)

• Anticholinergic agents: additive constipating effect may lead to severe constipation.
• Opioid analgesics: combined opioid effect may increase sedation or respiratory depression.
• Rifampin: enzyme inducer may reduce loperamide effectiveness.